A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: February 22, 2007
Last updated: May 31, 2012
Last verified: March 2011
This study will be conducted in healthy volunteers to investigate the effect on intraocular pressure of 2 weeks of treatment with 300mg WELLBUTRIN XL/day.

Condition Intervention Phase
Healthy Subjects
Depressive Disorder
Drug: WellbutrinXL
Drug: placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Diagnostic
Official Title: A Cross-over Study to Evaluate the Effect of WELLBUTRIN XL on Intraocular Pressure in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Intraocular pressure at Day -1, Days 1 & 14. [ Time Frame: at Day -1, Days 1 & 14. ]

Secondary Outcome Measures:
  • Intraocular pressure,Pupil diameter, anterior chamber angle [ Time Frame: Days-1,1&14 ]
  • Wellbutrin XL plasma level [ Time Frame: Days1,12-14 ]
  • adverse events [ Time Frame: each visit ]
  • lab tests,ECG,vital signs: [ Time Frame: screening,followup ]
  • lab tests: [ Time Frame: Days-2,13-14 ]
  • ECG: [ Time Frame: Day 14 ]
  • vital signs: [ Time Frame: Days-2,-1,1,14 ]

Enrollment: 33
Study Start Date: February 2007
Intervention Details:
    Drug: WellbutrinXL Drug: placebo
    Other Name: WellbutrinXL

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy males or females.
  • Non-smokers
  • Agree to remain in the clinic for the time defined in the protocol.
  • Normal ECG.

Exclusion Criteria:

  • Any serious medical disorder or condition.
  • Any history of an endocrine disorder.
  • Any clinically significant laboratory abnormality.
  • History of psychiatric illness.
  • Any history of suicidal attempts or behavior.
  • Risk factors for precipitation of angle closure glaucoma or elevated IOP.
  • Inability to refrain from use of contact lenses during the study days, if correction is required.
  • Self-administered Beck Depression Inventory II scale total score greater than 9, and a suicide question score of greater than zero.
  • Current or past history of seizure disorder or brain injury (traumatic or disease-related); or any condition which, in the opinion of the investigator, predisposes to seizure - Women having a positive serum HCG pregnancy test at screening, a positive urine pregnancy test before admission to the Unit during the in-house periods, who are not willing to use acceptable methods of contraception or who are lactating or planning to become pregnant within the three months following the screening visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00439868

United States, Florida
GSK Investigational Site
Gainesville, Florida, United States, 32605
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00439868     History of Changes
Other Study ID Numbers: WXL108709 
Study First Received: February 22, 2007
Last Updated: May 31, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
WELLBUTRIN XL, intraocular pressure, healthy volunteers

Additional relevant MeSH terms:
Depressive Disorder
Behavioral Symptoms
Mental Disorders
Mood Disorders
Antidepressive Agents
Antidepressive Agents, Second-Generation
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Dopamine Agents
Dopamine Uptake Inhibitors
Enzyme Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Psychotropic Drugs

ClinicalTrials.gov processed this record on May 25, 2016